HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Rhea-AI Summary

HOPE Therapeutics (Nasdaq: NRXP) opened a Palm Beach, FL clinic on March 9, 2026, offering one‑day interventional psychiatry treatments for depression and PTSD that combine ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen, and physician‑led psychotherapy.

Peer‑reviewed publications cited an 87% clinical response rate for a short‑term TMS plus neuroplastic medication protocol; pilot programs with added hyperbaric oxygen reported a 90% return to full function rate. HOPE cites a nationwide partnership with neurocare AG and is now accepting patients by phone.

Positive

• Opened Palm Beach clinic on March 9, 2026
• 87% published clinical response for short‑term TMS plus neuroplastic drugs
• Pilot programs reported 90% return to full function with hyperbaric oxygen
• Nationwide partnership with neurocare AG to bring non‑invasive treatments

Negative

• Published response rates may not predict outcomes for individual patients
• Hyperbaric oxygen results reported as pilot data, not definitive randomized trials

News Market Reaction – NRXP

+1.76%

9 alerts

+1.76% News Effect

+14.2% Peak in 26 hr 24 min

+$1M Valuation Impact

$59M Market Cap

0.4x Rel. Volume

On the day this news was published, NRXP gained 1.76%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $59M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

TMS response rate: 87% Return to full function: 90% Traditional antidepressant efficacy: 37%

3 metrics

TMS response rate 87% Clinical response to non-invasive TMS with neuroplastic medications in published results

Return to full function 90% Pilot programs with hyperbaric oxygen for depression and PTSD

Traditional antidepressant efficacy 37% Stated effectiveness rate for traditional antidepressants before modern neuroplastic therapies

Market Reality Check

Price: $1.80 Vol: Volume 462,642 vs 20-day ...

normal vol

$1.80 Last Close

Volume Volume 462,642 vs 20-day average 532,954, indicating slightly muted trading. normal

Technical Shares at $1.70 are trading below the 200-day MA of $2.65 and about 55.73% under the 52-week high.

Peers on Argus

NRXP was down 3.95% while peers showed mixed moves: gains in IMMX (11.26%) and S...

NRXP was down 3.95% while peers showed mixed moves: gains in IMMX (11.26%) and SLGL (8.22%), declines in ABVC (-4.29%) and MGX (-4.52%), suggesting stock-specific factors rather than a unified sector trend.

Previous Offering Reports

3 past events · Latest: Jan 05 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Clinic network partnership	Positive	-8.0%	Nationwide neuroplastic therapy clinic network with neurocare AG for depression and PTSD.
Apr 18	Public offering priced	Negative	-27.8%	Pricing of $2.0M underwritten public offering of common stock.
Apr 17	Public offering proposed	Negative	-27.8%	Announcement of proposed underwritten public offering of common stock.

Pattern Detected

Offering-related announcements have often coincided with negative price moves, including a decline after a positive clinic-partnership expansion, indicating sensitivity to financing and commercialization structures.

Recent Company History

Over recent offering-tagged events, NRx used news to advance both financing and commercialization. On Jan 5, 2026, it announced a nationwide clinic network partnership with neurocare AG, but the stock fell 8.02%. In April 2024, both a proposed and a priced underwritten public offering each saw -27.75% reactions, underscoring investor concern around dilution. Today’s HOPE Therapeutics clinic opening fits the same neuroplastic-therapy rollout theme but contrasts with the more financing-centric 2024 offerings.

Historical Comparison

-21.2% avg move · In past offering-tagged announcements, NRXP moved an average of -21.17%, showing that financing or c...

offering

-21.2%

Average Historical Move offering

In past offering-tagged announcements, NRXP moved an average of -21.17%, showing that financing or commercialization offers have frequently been met with selling pressure.

Offering-tagged history shows progression from financing-driven stock offerings in 2024 to a January 2026 nationwide clinic partnership, now followed by a new flagship clinic opening under HOPE Therapeutics.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2025-12-12

$150,000,000 registered capacity

An effective S-3/A shelf filed on 2025-12-12 allows NRx to offer up to $150,000,000 in various securities over time, providing flexible capital access but also potential future equity or debt issuance.

Market Pulse Summary

This announcement highlights expansion of HOPE Therapeutics’ clinic network via a Palm Beach site of...

Analysis

This announcement highlights expansion of HOPE Therapeutics’ clinic network via a Palm Beach site offering TMS, ketamine-based neuroplastic therapy, and hyperbaric oxygen for depression and PTSD, citing response rates up to 87–90% in published and pilot data. It builds on earlier partnership plans with neurocare AG and a broader neuroplastic-therapy strategy. Investors may watch for patient volume, reimbursement dynamics, and how clinic performance interacts with NRx’s existing $150,000,000 shelf and overall funding needs.

Key Terms

transcranial magnetic stimulation, hyperbaric oxygen, post-traumatic stress disorder, Alzheimer’s disease, +2 more

6 terms

transcranial magnetic stimulation medical

"treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen"

A noninvasive medical treatment that uses a changing magnetic field delivered through a coil placed near the head to stimulate specific areas of the brain, much like tapping a piano key to make a particular note play. Investors care because devices, clinical trial results, insurance coverage, and regulatory approvals determine commercial adoption and revenue potential for makers of the machines, clinics that offer the therapy, and related healthcare suppliers.

hyperbaric oxygen medical

"includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen, combined with physician-led psychotherapy"

Hyperbaric oxygen is a medical treatment where a person breathes pure oxygen inside a sealed chamber at higher-than-normal air pressure, which forces more oxygen into the blood and tissues than ordinary breathing. For investors, it matters because the equipment, clinics, and approved medical uses create business opportunities and regulatory risks; think of the chamber like temporarily increasing a delivery truck’s capacity so oxygen can reach damaged areas and speed healing, driving demand, insurance coverage, and research investment.

post-traumatic stress disorder medical

"return to full function in patients with depression and post-traumatic stress disorder"

A mental health condition that can develop after a person experiences or witnesses a traumatic event, causing persistent symptoms such as intrusive memories, heightened stress reactions, avoidance of reminders, and trouble sleeping or concentrating. For investors it matters because it can reduce employee productivity, increase healthcare and disability costs, alter consumer behavior, and create demand for treatment and support services—think of a business whose systems keep freezing after a shock, requiring ongoing fixes and higher operating costs.

Alzheimer’s disease medical

"improved memory and cognition in some patients with Alzheimer’s disease and Traumatic Brain Injury"

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

Traumatic Brain Injury medical

"improved memory and cognition in some patients with Alzheimer’s disease and Traumatic Brain Injury"

Traumatic brain injury (TBI) is damage to the brain caused by a sudden external force—like a blow, jolt, or penetration—that disrupts thinking, movement, senses, or emotion; think of the brain as a delicate computer that can short-circuit after a hard impact. For investors, TBI matters because it drives demand for medical devices, drugs, rehabilitation services, and long-term care, and it creates financial risks for insurers and companies facing liability or costly clinical research and regulatory hurdles.

ketamine medical

"approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS)"

A fast-acting anesthetic drug that is also used at lower doses to treat severe depression and certain pain conditions; it works differently from traditional antidepressants and can produce rapid symptom relief, often described as a short-term “reset” of brain activity. Investors watch ketamine because clinical trial results, regulatory approvals, safety concerns, legal status, production scale, and potential off-label use drive demand, pricing, and the business prospects of companies involved in its manufacture and delivery.

AI-generated analysis. Not financial advice.

• Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.
• Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.
• Now accepting patients, call 1-833-4HOPETMS
  
  

WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine¹ and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen, combined with physician-led psychotherapy. This clinic location is the most recent addition to HOPE’s growing network of clinics.

Peer-reviewed scientific publications have shown an 87% clinical response rate with a short-term treatment protocol in patients with treatment-resistant depression. With the addition of hyperbaric oxygen therapy, pilot programs have shown a 90% rate of return to full function in patients with depression and post-traumatic stress disorder. TMS has also been shown in some studies to demonstrate improved memory and cognition in some patients with Alzheimer’s disease and Traumatic Brain Injury. HOPE previously announced a nationwide partnership with neurocare AG and expects to bring the latest developments in the non-invasive treatment of these conditions to this flagship location.

“Prior to the advent of modern neuroplastic therapies for depression, PTSD, and related conditions, patients were primarily treated with traditional antidepressants which are now understood to work only 37% of the time and to have a broad array of negative side effects. In severe cases, the only FDA-approved treatment was electroshock therapy. We at HOPE are thrilled to be able to offer state-of-the-art neuroplastic therapy with a potential for rapid return to functional daily life, often without the need for daily medications,” said Dr. Jonathan Javitt, CEO of HOPE Therapeutics. 

The clinical results that have been published in the medical literature are based on a broad array of patients and may or may not reflect the results achieved by any individual patient.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetics stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve rapid remission from treatment resistant depression.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

^{__________________
1} Ketamine is currently FDA-approved as an anesthetic but is not indicated for use in treating depression, although it is used by practicing physicians for that purpose and is the subject of numerous scientific publications. It has been identified by the US Department of Veterans Affairs as a drug that may be "medically necessary" for "Treatment Resistant Depression" and for "Depression with severe suicidal ideation. The appropriateness of ketamine for any particular patient is a doctor/patient decision that can only be made within the scope of clinical practice of medicine.

FAQ

What treatment options does HOPE Therapeutics (NRXP) offer at the Palm Beach clinic?

HOPE offers one‑day interventional psychiatry combining ketamine, other neuroplastic drugs, TMS, hyperbaric oxygen, and physician‑led psychotherapy. According to the company, these modalities are delivered together as a rapid‑treatment approach for depression and PTSD.

What clinical response rates has HOPE cited for TMS with neuroplastic medications (NRXP)?

The company cites an 87% clinical response rate in peer‑reviewed publications for a short‑term TMS plus neuroplastic medication protocol. According to the company, those results derive from published studies and may not reflect individual patient outcomes.

How effective is adding hyperbaric oxygen therapy at HOPE's clinics for depression and PTSD?

HOPE reports pilot programs showing a 90% rate of return to full function when hyperbaric oxygen is added. According to the company, these are pilot results and may not be confirmed by larger randomized trials.

Is the Palm Beach HOPE clinic accepting patients and how can they schedule (NRXP)?

Yes, the Palm Beach clinic is accepting patients. According to the company, prospective patients can call 1‑833‑4HOPETMS to inquire about appointments and treatment options.

What partnership supports HOPE Therapeutics' treatments at the new NRXP clinic?

HOPE cites a nationwide partnership with neurocare AG to bring the latest non‑invasive treatment developments to its clinics. According to the company, this partnership underpins clinical offerings at the flagship Palm Beach location.